WUH: AMPLATZER Amulet Left Atrial Appendage (LAA) Occluder Randomized Controlled Trial
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Non-valvular Atrial Fibrillation
-
Age: Between 18 Year(s) - 80 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Subjects with documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation and has not been diagnosed with rheumatic mitral valvular heart disease
- Subjects who are at high risk of stroke or systemic embolism
- Subjects has an appropriate rationale to seek an alternative to warfarin or other anticoagulant medication
- Subjects deemed by investigator to be suitable for short term warfarin therapy but deemed unable to take long term anticoagulation
- Subjects deemed suitable for LAA closure
- Subjects able to comply with the required medication regime post-device implant
- Subjects able to understand and is willing to provide written informed consent to participate in the trial
- Subjects able and willing to return for required follow-up visits and examinations
You may not be eligible for this study if the following are true:
-
- Subjects requires long-term oral anticoagulation therapy for a condition other than atrial fibrillation
- Subjects who are contraindicated for or allergic to aspirin, clopidogrel, or warfarin use
- Subjects indicated for chronic P2Y12 platelet therapy inhibitor
- Subjects is considered at high risk for general anesthesia, in the opinion of the investigator, and/or based on past adverse reaction(s) requiring medical intervention or which resulted in prolongation of hospital stay
- Subjects has undergone atrial septal defect (ASD) repair or has an ASD closure device present
- Subjects has undergone patent foramen ovale (PFO) repair or has a PFO closure device implanted
- . Subjects implanted with a mechanical valve prosthesis
- . Subjects has any of the customary contraindications for a percutaneous catheterization procedure
- Subjects has had a stroke or transient ischemic attack (TIA) within 90 days prior to randomization or implant procedure
- Subjects who underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to randomization, or intervention or surgery is planned within 60 days after implant procedure
- Those who had myocardial infarction (MI) within 90 days prior to randomization
- New York Heart Association Class IV Congestive Heart Failure
- Subjects with symptomatic carotid disease
- History of idiopathic or recurrent venous thromboembolism
- Subjects who are pregnant or pregnancy is planned.
- Subjects with severe renal failure
- Subject has had a transient case of AF
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.